Anti-Mullerian Hormone (AMH) in Gynecological Endocrinology

Anti-Müllerian hormone (AMH), also known as Mullerian inhibiting substance (MIS), is a dimeric protein member of the TGF-β subfamily (1). AMH is produced by the granulosa cells of pre-antral and small antral follicles. Follicular growth is modulated by AMH, which inhibits recruitment of follicles from the primordial pool by modifying the FSH sensitivity of those follicles. As a follicle matures, AMH production disappears allowing the follicle to complete the development process (2).

[1]  Hyo-Kyoung Nam,et al.  Serum Anti-Müllerian Hormone Levels in Precocious Puberty Girls according to Stage of GnRH Agonist Treatment , 2017, Journal of Korean medical science.

[2]  Mehrnoosh Maalhagh,et al.  Comparison of Specificity and Sensitivity of AMH and FSH in Diagnosis of Premature Ovarian Failure , 2015, Disease markers.

[3]  Richard A. Anderson,et al.  AMH as Predictor of Premature Ovarian Insufficiency: A Longitudinal Study of 120 Turner Syndrome Patients. , 2015, The Journal of clinical endocrinology and metabolism.

[4]  Urvashi B Singh,et al.  Anti-Mullerian Hormone: A New Marker of Ovarian Function , 2014, The Journal of Obstetrics and Gynecology of India.

[5]  M. Ranke,et al.  Anti-Müllerian hormone levels in girls and adolescents with Turner syndrome are related to karyotype, pubertal development and growth hormone treatment. , 2013, Human reproduction.

[6]  J. Visser,et al.  Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency , 2012, Nature Reviews Endocrinology.

[7]  A. Duhamel,et al.  Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. , 2011, Human reproduction.

[8]  D. Panidis,et al.  The clinical significance of anti-Müllerian hormone evaluation in gynecological endocrinology , 2011, Hormones.

[9]  A. El‐Mazny,et al.  Anti-Müllerian hormone in polycystic ovary syndrome and normo-ovulatory women: Correlation with clinical, hormonal and ultrasonographic parameters , 2010 .

[10]  D. Barad,et al.  Discordances between follicle stimulating hormone (FSH) and anti-Müllerian hormone (AMH) in female infertility , 2010, Reproductive biology and endocrinology : RB&E.

[11]  B. Mol,et al.  The role of anti-Müllerian hormone assessment in assisted reproductive technology outcome , 2010, Current opinion in obstetrics & gynecology.

[12]  A. Volpe,et al.  Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). , 2010, Human reproduction update.

[13]  A. Aflatoonian,et al.  Prediction of high ovarian response to controlled ovarian hyperstimulation: anti-Müllerian hormone versus small antral follicle count (2–6 mm) , 2009, Journal of Assisted Reproduction and Genetics.

[14]  P. Devroey,et al.  Approaches to improve the diagnosis and management of infertility , 2009, Human reproduction update.

[15]  B. Mol,et al.  The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. , 2009, Fertility and sterility.

[16]  M. Yosef,et al.  Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. , 2008, The Journal of clinical endocrinology and metabolism.

[17]  B. Mol,et al.  A systematic review of tests predicting ovarian reserve and IVF outcome. , 2006, Human reproduction update.

[18]  O. Shebl,et al.  Basal level of anti-Müllerian hormone is associated with oocyte quality in stimulated cycles. , 2006, Human reproduction.

[19]  A. Volpe,et al.  Anti‐Müllerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool? , 2006, Clinical endocrinology.

[20]  A. Themmen.  Anti-Müllerian hormone: its role in follicular growth initiation and survival and as an ovarian reserve marker. , 2005, Journal of the National Cancer Institute. Monographs.

[21]  J. Segars,et al.  A prospective assessment of the predictive value of basal antral follicles in in vitro fertilization cycles. , 2003, Fertility and sterility.

[22]  P. Donahoe,et al.  The role of Müllerian inhibiting substance in the evaluation of phenotypic female patients with mild degrees of virilization. , 2003, The Journal of clinical endocrinology and metabolism.

[23]  P. Pearson,et al.  The variability of female reproductive ageing. , 2002, Human reproduction update.

[24]  J. Habbema,et al.  Predictors of poor ovarian response in in vitro fertilization: a prospective study comparing basal markers of ovarian reserve. , 2002, Fertility and sterility.

[25]  Hum Reproduct.  Anti-Mullerian hormone ( AMH ) : what do we still need to know ? , 2015 .

[26]  M. Eijkemans,et al.  Comparison of inter- and intra-cycle variability of anti-Mullerian hormone and antral follicle counts. , 2010, Human reproduction.

[27]  L. Aucott,et al.  Interventions for 'poor responders' to controlled ovarian hyperstimulation (COH) in in-vitro fertilisation (IVF). , 2007, The Cochrane database of systematic reviews.

[28]  J. Visser,et al.  Anti-Müllerian hormone: a new marker for ovarian function. , 2006, Reproduction.